ClinicalTrials.gg
Not yet recruitingNCT07783906Updated Nov 18, 2026

Precision Closed-loop Brain-Computer Interface Neuromodulation for Treatment-Resistant Depression

An interventional study of Closed-loop Deep Brain Stimulation (DBS) and Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Treatment-Resistant Major Depressive Disorder and Major Depressive Disorder, sponsored by Shanghai Mental Health Center. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center — 12 open to participants now, 12 under way, none of them phase 3. Depressive Disorder, Major · Shanghai Mental Health Center.

Planned enrollment
28th of 32
70 · median 180
Started
2026
with 4 others
No phase
17 of 40
5 open now
Primary completion
2028-12
later than 10 of 11 live
Registered
40th of 40
by date

Among the 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center, this one is the 28th largest by planned enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2026, is one of 17 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 40th registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

12 of the 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 415 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 295 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Depressive Disorder, Major by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether precision closed-loop neuromodulation treatments can improve depressive symptoms and daily functioning in people with treatment-resistant major depressive disorder (TRD). The study will assess the effectiveness and safety of two neuromodulation approaches: closed-loop deep brain stimulation (DBS) and transcutaneous auricular vagus nerve stimulation (taVNS).

Treatment-resistant major depressive disorder refers to depression that does not improve sufficiently after adequate treatment with standard antidepressant therapies. This study focuses on people with TRD, including individuals with early-onset depression, a history of self-harm or suicidal thoughts, or depression associated with traumatic experiences.

This study aims to answer whether closed-loop DBS and taVNS can reduce depressive symptoms compared with sham stimulation, whether these treatments are safe and well tolerated, and whether changes in brain activity are associated with clinical improvement.

This is a multicenter, prospective clinical study conducted at Shanghai Mental Health Center, Beijing Anding Hospital, and Xuanwu Hospital. Eligible participants with TRD will receive either DBS or taVNS according to patient preference. Within each intervention group, participants will be randomly assigned to active stimulation or sham stimulation groups to assess treatment effects.

During the study, participants will receive neuromodulation treatment and complete regular follow-up assessments. These assessments will include evaluation of depressive symptoms, anxiety symptoms, cognitive function, social functioning, brain electrical activity using electroencephalography (EEG), brain imaging using magnetic resonance imaging (MRI), and monitoring of adverse events.

The study will compare changes in clinical symptoms, brain-related measures, and safety outcomes between active and sham stimulation groups. The findings may help determine whether precision neuromodulation approaches can provide a new treatment option for people with treatment-resistant major depressive disorder.

03

Conditions studied

  • Treatment-Resistant Major Depressive Disorder
  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 70 years, regardless of sex.
  • At least primary school education and able to understand the content of the assessment scales.
  • Meet the diagnostic criteria for depressive disorders according to the , Fifth Edition (DSM-5).
  • Have a history of depression lasting at least 24 months and have received adequate-dose and adequate-duration treatment with at least 2 antidepressants for 8 weeks or longer, including electroconvulsive therapy without anesthesia, with a reduction rate in the HAMD-17 score of 20% or less after treatment.
  • Have a HAMD-17 score greater than 17 at baseline.
  • Have been on a stable regimen of the current antidepressant medication for at least 1 month before enrollment.
  • Meet at least one of the following three criteria:

    1. Depression with onset before 18 years of age.

      1. The age at first depressive episode was younger than 18 years, confirmed by a psychiatrist at the attending physician level or above according to the DSM-5 or International Classification of Diseases, 11th Revision (ICD-11) diagnostic criteria for depressive disorders.
      2. The age at onset can be supported by at least one of the following sources: the participant's medical history report, previous medical records, or information about age at onset provided by a guardian.
      3. If the onset age is unclear, confirmation requires consistency between at least two independent sources of information.
    2. A clear history of self-injurious or suicidal behavior:

      1. As confirmed by a guardian or through review of previous medical records, the participant has had self-injurious behavior, such as cutting, burning, hitting oneself, involving intentional self-harm without the intent to die; or suicidal behavior or tendencies, such as recurrent suicidal ideation, suicidal planning, or a suicide attempt.
      2. Such behavior or tendencies must be documented in, but not limited to, outpatient or inpatient medical records, psychological assessment records, or school or community referral records. Alternatively, they may be clearly described by a guardian and documented and confirmed in writing by the investigator.
    3. A clear history of traumatic stress:

      1. As confirmed by a guardian or through review of previous medical records, before the onset or worsening of depression, the participant experienced a situation meeting the DSM-5 definition of traumatic events, including but not limited to: actual or threatened death; serious injury; sexual violence; abuse; neglect; bullying; major accidents; war; natural disasters; intimate partner violence.
      2. The traumatic event must have a clearly documented time of occurrence, type of event, and temporal relationship with the onset or worsening of depressive symptoms.
      3. Standardized instruments such as life event questionnaires may be used as supplementary assessments. However, final eligibility determination must be made by the investigator based on comprehensive evaluation of: information provided by the legal guardian; previous medical records; clinical judgment.
  • Participants or their legal guardians must voluntarily sign the form and must be capable of completing follow-up assessments;
  • Participants assigned to the DBS group must pass preoperative evaluation for DBS surgery and must have no for neurosurgical procedures;
  • Participants assigned to the taVNS group must pass taVNS eligibility assessment, including: no recent facial or auricular injuries; no metallic implants in the head or heart; no active gastrointestinal symptoms; no acute exacerbation of respiratory disorders; no personal or family history of epilepsy; no frequent or severe headaches.

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of: schizophrenia; schizoaffective disorder; substance dependence or drug addiction; mental disorders secondary to other medical conditions; or presence of significant psychotic symptoms, including delusions and hallucinations.
  • Presence of severe or unstable disorders involving the: central nervous system; cardiovascular system; respiratory system; liver; kidney; endocrine system; hematological system; or other major organ systems, which, in the investigator's judgment, make the participant unsuitable for enrollment.
  • Female participants who are: pregnant; breastfeeding; planning pregnancy during the study period or within 8 weeks after the last medication administration; or male participants with plans for reproduction during the study period.
  • Participation in another clinical trial within the previous 3 months.
  • Inability to undergo MRI examination.
  • MRI findings indicating any of the following: more than two lacunar infarcts; regional infarction lesions with a volume >1 cm³; significant white matter lesions; a total Fazekas score of 3.
  • Severe aphasia, visual impairment, hearing impairment, or other conditions preventing completion of study procedures.
  • Any condition that, in the investigator's opinion, makes the participant unsuitable for participation in this study.
  • to DBS surgery or chronic vagus nerve stimulation (VNS).
  • High suicide risk determined using the Columbia-Suicide Severity Rating Scale (C-SSRS). Participants will be excluded if any of the following criteria are met:

    1. A suicide attempt within the previous 3 months;
    2. Persistent active suicidal ideation with intent to act, as indicated by the C-SSRS assessment;
    3. Emergency department visit or hospitalization due to suicide risk within 1 month prior to enrollment;
    4. Baseline C-SSRS assessment indicates non-persistent active suicidal ideation, but the investigator determines, based on the intensity of suicidal intent score (C-SSRS Item 5) and clinical evaluation, that the participant has severely impaired impulse control and immediate suicide risk, confirmed by a psychiatric specialist.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Active DBS

    Participants will receive active closed-loop deep brain stimulation (DBS). After DBS implantation surgery, stimulation will be activated 7-14 days after surgery. Participants will receive closed-loop DBS treatment and undergo clinical follow-up assessments for 8 weeks to evaluate changes in depressive symptoms, cognitive function, and safety outcomes.

    Device: Closed-loop Deep Brain Stimulation (DBS)

  • Sham comparator
    Sham DB

    Participants will receive sham deep brain stimulation (DBS) during the blinded comparison period. After DBS implantation surgery, stimulation will remain inactive until 8 weeks after surgery. Participants will undergo the same clinical follow-up assessments as the active DBS group during the study period.

    Device: Closed-loop Deep Brain Stimulation (DBS)

  • Experimental
    Active taVNS

    Participants will receive active transcutaneous auricular vagus nerve stimulation (taVNS). Electrical stimulation will be delivered through electrodes placed at the auricular stimulation sites. Participants will receive taVNS treatment and undergo clinical follow-up assessments for 8 weeks to evaluate changes in depressive symptoms, cognitive function, and safety outcomes.

    Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

  • Sham comparator
    Sham taVNS

    Participants will receive sham transcutaneous auricular vagus nerve stimulation (taVNS). The electrodes will be placed at the same auricular sites as active stimulation, but no therapeutic electrical stimulation will be delivered. Participants will undergo the same clinical follow-up assessments as the active taVNS group.

    Device: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Interventions

  • DeviceClosed-loop Deep Brain Stimulation (DBS)

    Closed-loop deep brain stimulation (DBS) is an implanted neuromodulation intervention that delivers electrical stimulation based on real-time neural signals. Participants assigned to the DBS pathway will undergo implantation of a DBS system and receive either active or delayed stimulation according to the randomized study assignment. Clinical outcomes, cognitive function, brain activity, and safety outcomes will be assessed during follow-up.

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulation (taVNS)

    Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation intervention that delivers electrical stimulation through electrodes placed on auricular sites associated with the vagus nerve. Participants assigned to the taVNS pathway will receive either active or sham stimulation according to the randomized study assignment. Clinical outcomes, cognitive function, brain activity, and safety outcomes will be assessed during follow-up.

06

What researchers measure

Primary outcomes

  1. Change in 17-item Hamilton Rating Scale for Depression (HAMD-17) score

    The primary efficacy outcome is the change in the 17-item Hamilton Depression Rating Scale (HAMD-17) score from baseline to week 8 after intervention. The HAMD-17 is used to assess the severity of depressive symptoms, with higher scores indicating greater severity of depressive symptoms. A decrease in HAMD-17 score indicates improvement in depressive symptoms.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Hamilton Anxiety Rating Scale (HAMA) score

    The change in Hamilton Anxiety Rating Scale (HAMA) score from baseline to Week 8 will be evaluated to assess changes in anxiety symptom severity. The HAMA total score ranges from 0 to 56, with higher scores indicating greater severity of anxiety symptoms. A decrease in HAMA score indicates improvement in anxiety symptoms.

    Time frame: Baseline to Week 8

  2. Change in Montreal Cognitive Assessment scale (MoCA) score

    The change in Montreal Cognitive Assessment (MoCA) score from baseline to Week 8 will be evaluated to assess changes in cognitive function. The MoCA total score ranges from 0 to 30, with higher scores indicating better cognitive function. An increase in MoCA score indicates improvement in cognitive function.

    Time frame: Baseline to Week 8

  3. Change in Montgomery-Asberg Depression Rating Scale (MADRS) score

    The change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to Week 8 will be evaluated to assess changes in depressive symptom severity. The MADRS total score ranges from 0 to 60, with higher scores indicating greater severity of depressive symptoms. A decrease in MADRS score indicates improvement in depressive symptoms.

    Time frame: Baseline to Week 8

  4. Change in Patient Health Questionnaire-9 (PHQ-9) score

    The change in Patient Health Questionnaire-9 (PHQ-9) score from baseline to Week 8 will be evaluated to assess changes in depressive symptoms. The PHQ-9 total score ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms. A decrease in PHQ-9 score indicates improvement in depressive symptoms.

    Time frame: Baseline to Week 8

  5. Change in Generalized Anxiety Disorder-7 (GAD-7) score

    The change in Generalized Anxiety Disorder-7 (GAD-7) score from baseline to Week 8 will be evaluated to assess changes in anxiety symptoms. The GAD-7 total score ranges from 0 to 21, with higher scores indicating greater severity of anxiety symptoms. A decrease in GAD-7 score indicates improvement in anxiety symptoms.

    Time frame: Baseline to Week 8

  6. Change in Clinical Global Impression-Improvement (CGI) score, using Clinical Global Impression-Severity (CGI-S)

    The change in Clinical Global Impression-Severity (CGI-S) score from baseline to each follow-up assessment will be evaluated to assess changes in overall illness severity. The CGI-S is rated on a 7-point scale from 1 to 7, with higher scores indicating greater illness severity. A decrease in CGI-S score indicates improvement in overall illness severity.

    Time frame: Baseline to Week 8

  7. Change in Clinical Global Impression-Improvement (CGI) score, using Clinical Global Impression-Improvement (CGI-I).

    The Clinical Global Impression-Improvement (CGI-I) score will be used to assess overall clinical improvement relative to baseline. The CGI-I is rated on a 7-point scale from 1 to 7, with 1 indicating very much improved, 4 indicating no change, and 7 indicating very much worse. Lower scores indicate greater clinical improvement.

    Time frame: Baseline to Week 8

  8. Change in Personal and Social Performance Scale (PSP) score

    The change in Personal and Social Performance (PSP) Scale score from baseline to each follow-up assessment will be evaluated to assess changes in personal and social functioning. The PSP total score ranges from 1 to 100, with higher scores indicating better personal and social functioning. An increase in PSP score indicates improvement in personal and social functioning.

    Time frame: Baseline to Weeks 1, 2, 4, 6, and 8

  9. Change in Social Functioning Rating Scale (SFRS) score

    The change in Social Functioning Rating Scale (SFRS) score from baseline to Week 8 will be evaluated to assess changes in social functioning. The SFRS consists of 36 items, with each item scored from 0 to 7, resulting in a total score ranging from 0 to 252. Higher scores indicate poorer social functioning. A decrease in SFRS score indicates improvement in social functioning.

    Time frame: Baseline to Week 8

  10. EEG Delta, Theta, Alpha, and Beta Band Power and Theta/Beta Power Ratio

    EEG recordings will be analyzed to quantify changes in spectral power across predefined frequency bands, including delta (0.5-4 Hz), theta (4-8 Hz), alpha (8-13 Hz), beta (13-30 Hz) bands, and theta/beta power ratio from baseline to week 8.

    Time frame: Baseline to Week 8

  11. Changes in neuroimaging measures assessed by magnetic resonance imaging (MRI)

    Time frame: Baseline to Week 8

  12. Number and percentage of participants with adverse events or serious adverse events

    Adverse events will be assessed throughout the study period. Clinically significant findings from laboratory tests, vital signs, electrocardiography, and other examinations will be recorded as adverse events when considered clinically significant by the investigator. When a specific clinical diagnosis can be made, the diagnosis will be recorded as the adverse event; when no specific diagnosis can be made, the clinical significance will be determined by the investigator. Adverse events will be classified as mild, moderate, or severe, and their occurrence time, severity, duration, management, and outcome will be recorded. The number and percentage of participants experiencing adverse events will be summarized.

    Time frame: Baseline to Week 8

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 653 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 24 months is below that.

Counting every sponsor, half of 693 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 25, 2026
StartEst.
Dec 2026was Aug 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Dec 2026
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Aug 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07783906
Collaborators
Xuanwu Hospital, Beijing, Anding Hospital, Beijing
Responsible party
Lin SUN (Principal Investigator, Shanghai Mental Health Center) — Principal investigator
First posted
Aug 25, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion